Effects of Hypertension Alone and in Comorbidity with Diabetes on Death within 30 Days among Inpatients with COVID-19 Infection

Background: Hypertension and diabetes are common comorbidities in patients with COVID-19 and could be influencing the mortality of such patients. The present study aimed to evaluate the effects of hypertension alone and in comorbidity with diabetes on the death within 30 days among inpatients with COVID-19 in presence of well-known determinates of COVID-19 death. Study Design: A case-control study. Methods: Four groups of COVID-19 inpatients including controls, diabetes alone, hypertension alone, and hypertension and diabetes comorbidities were defined. Each study groups did not have underlying diseases other than hypertension and diabetes. Demographic and general characteristics, underlying diseases, and hospital course events were extracted from medical records. The outcome of interest was alive at discharge/ death within 30 days after admission. Multivariable binary logistic analysis was employed to estimate the effect measures. Results: The number of death within 30 days among controls (n=1359), diabetes alone (159), hypertension alone (406) and hypertension and diabetes comorbidities (188) were 12.68%, 15.72%, 20.74% and 26.74%, respectively. According to three multivariable analyses after adjusting older age, hospital length of stay, and intensive care unit (ICU) admission separately, the odds of death within 30 days in COVID-19 patients with having hypertension and diabetes comorbidities was 1.58, 2.13 and 1.91 times of patients without such comorbidities, respectively (P<0.015). The effect of hypertension alone was also significant after adjusting hospital length of stay and ICU admission but not for older age. Conclusion: Our results suggest that comorbidities, such as hypertension and diabetes may be associated with COVID-19-related deaths independent of other underlying diseases, older age, and adverse hospital course events.

[1]  I. Djaharuddin,et al.  Comorbidities and mortality in COVID-19 patients , 2021, Gaceta Sanitaria.

[2]  G. Severi,et al.  Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies , 2021, BMJ Open.

[3]  Yuting Wu,et al.  Effects of hypertension on the outcomes of COVID-19: a multicentre retrospective cohort study , 2021, Annals of medicine.

[4]  C. Cuspidi,et al.  The influence of diabetes and hypertension on outcome in COVID‐19 patients: Do we mix apples and oranges? , 2020, Journal of clinical hypertension.

[5]  K. He,et al.  Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID‐19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital , 2020, Journal of clinical hypertension.

[6]  J. E. L. Peña,et al.  Hypertension, Diabetes and Obesity, Major Risk Factors for Death in Patients with COVID-19 in Mexico , 2020, Archives of Medical Research.

[7]  D. Papazoglou,et al.  Diabetes Mellitus and Hypertension as Major Risk Factors of Mortality From Covid-19 Pneumonia. , 2020, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.

[8]  S. Jahanfar,et al.  Predictors of mortality in patients with COVID-19–a systematic review , 2020, European Journal of Integrative Medicine.

[9]  R. Gómez-Huelgas,et al.  Association of Hypertension with All-Cause Mortality among Hospitalized Patients with COVID-19 , 2020, Journal of clinical medicine.

[10]  N. López-Villalobos,et al.  Clinical characteristics and risk factors for mortality of patients with COVID-19 in a large data set from Mexico , 2020, Annals of Epidemiology.

[11]  K. Khunti,et al.  Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: a population-based cohort study , 2020, The Lancet Diabetes & Endocrinology.

[12]  E. Schiffrin,et al.  Prevalence of Diabetes and Hypertension and Their Associated Risks for Poor Outcomes in Covid-19 Patients , 2020, Journal of the Endocrine Society.

[13]  A. Sanyaolu,et al.  Comorbidity and its Impact on Patients with COVID-19 , 2020, SN Comprehensive Clinical Medicine.

[14]  M. Ben-Shoshan,et al.  COVID-19 and comorbidities: a systematic review and meta-analysis , 2020, Postgraduate medicine.

[15]  R. Cianci,et al.  Age and Multimorbidity Predict Death Among COVID-19 Patients , 2020, Hypertension.

[16]  P. Serruys,et al.  Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study , 2020, European heart journal.

[17]  Xuanzhe Zhang,et al.  Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study , 2020, Diabetes Care.

[18]  Xiang Chen,et al.  Clinical determinants for fatality of 44,672 patients with COVID-19 , 2020, Critical Care.

[19]  Eun Ji Kim,et al.  Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. , 2020, JAMA.

[20]  R. Pranata,et al.  Hypertension is associated with increased mortality and severity of disease in COVID-19 pneumonia: A systematic review, meta-analysis and meta-regression , 2020, Journal of the renin-angiotensin-aldosterone system : JRAAS.

[21]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[22]  Wei Wang,et al.  Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis , 2020, European Respiratory Journal.

[23]  Zunyou Wu,et al.  Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. , 2020, JAMA.

[24]  Ziad A Memish,et al.  Clinical outcomes of current medical approaches for Middle East respiratory syndrome: A systematic review and meta‐analysis , 2018, Reviews in medical virology.

[25]  D. Kristoffersen,et al.  30-Day Survival Probabilities as a Quality Indicator for Norwegian Hospitals: Data Management and Analysis , 2015, PloS one.